Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CSF3R W341C |
| Therapy | Ruxolitinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CSF3R W341C | hematologic cancer | sensitive | Ruxolitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Jakafi (ruxolitinib) inhibited viability of a cell line expressing CSF3R W341C in culture (PMID: 28652245). | 28652245 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (28652245) | Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. | Full reference... |